Drug · DIN 02496887
NAT-BENDAMUSTINE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 25, 2021; first marketed February 25, 2021.
- Drug Identification Number (DIN)
- 02496887
- Company (DIN owner)
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Bendamustine L01AA09
- Class
- Human
- Record last updated
- July 20, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BENDAMUSTINE HYDROCHLORIDE | 25 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 29, 2024: NOC 32804Supplement to an Abbreviated New Drug Submission (SANDS) · Control of drug product: change in the specification for the drug product
- June 30, 2021: NOC 25279Abbreviated New Drug Submission (ANDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “nat-bendamustine”. A notice may cover another product or only some lots: read it to see what it covers.
- NAT-Bendamustine: DiscolorationDecember 6, 2022 · Drugs · Product quality · Type II
Other DINs named NAT-BENDAMUSTINE
- DIN 02496895 · Marketed